Authors
Ignace Vergote, Claes G Tropé, Frédéric Amant, Gunnar B Kristensen, Tom Ehlen, Nick Johnson, René HM Verheijen, Maria EL Van Der Burg, Angel J Lacave, Pierluigi Benedetti Panici, Gemma G Kenter, Antonio Casado, Cesar Mendiola, Corneel Coens, Leen Verleye, Gavin CE Stuart, Sergio Pecorelli, Nick S Reed
Publication date
2010/9/2
Journal
New England Journal of Medicine
Volume
363
Issue
10
Pages
943-953
Publisher
Massachusetts Medical Society
Description
Background
Primary debulking surgery before initiation of chemotherapy has been the standard of care for patients with advanced ovarian cancer.
Methods
We randomly assigned patients with stage IIIC or IV epithelial ovarian carcinoma, fallopian-tube carcinoma, or primary peritoneal carcinoma to primary debulking surgery followed by platinum-based chemotherapy or to neoadjuvant platinum-based chemotherapy followed by debulking surgery (so-called interval debulking surgery).
Results
Of the 670 patients randomly assigned to a study treatment, 632 (94.3%) were eligible and started the treatment. The majority of these patients had extensive stage IIIC or IV disease at primary debulking surgery (metastatic lesions that were larger than 5 cm in diameter in 74.5% of patients and larger than 10 cm in 61.6%). The largest residual tumor was 1 cm or less in diameter in 41.6% of patients after primary debulking …
Total citations
Scholar articles
I Vergote, CG Tropé, F Amant, GB Kristensen, T Ehlen… - New England Journal of Medicine, 2010